Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13510949 | 1.00 | ADRB2 (0.41) | ADRB2CYP3A4SERPINE1NPC1ALDH1A1 | |
| SCHEMBL925596 | 0.85 | ADRB2 (0.41) | ADRB2CYP3A4NPC1ALDH1A1LMNA | |
| SCHEMBL2831936 | 0.85 | ADRB2 (0.41) | ADRB2CYP3A4NPC1ALDH1A1LMNA | |
| SCHEMBL925593 | 0.85 | ADRB2 (0.41) | ADRB2CYP3A4NPC1ALDH1A1LMNA | |
| SCHEMBL28746933 | 0.81 | ADRB2 (0.61) | ADRB2CYP3A4LMNAHIF1AADRB1 | |
| SCHEMBL3030894 | 0.81 | ADRB2 (0.61) | ADRB2CYP3A4LMNAHIF1AADRB1 | |
| SCHEMBL3024798 | 0.80 | ADRB2 (0.34) | ADRB2 | |
| SCHEMBL925393 | 0.79 | AVPR1A (0.37) | CYP3A4ALDH1A1LMNAKDM4DAVPR1A | |
| SCHEMBL12321368 | 0.78 | HDAC3 (0.48) | ADRB2CYP3A4SERPINE1NPC1 | |
| SCHEMBL28731919 | 0.76 | NPC1 (0.37) | ADRB2CYP3A4NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116024187-B | Enzymatic preparation method of vilantrum Luo Zhongjian | 合肥大学 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023097678-A1 | METHOD FOR SYNTHESIZING (R)-5-(2,2-DIMETHYL-4H-BENZO[D][1,3]DIOXIN-6-YL)OXAZOLIDIN-2-ONE | 广东莱佛士制药技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-113735816-B | Method for preparing chiral alcohol from ketone by using microchannel reactor | 安徽德信佳生物医药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | PERRIGO API LTD. (IL) | 2015-08-27 | — | — | US | disclosed |
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | PERRIGO API LTD. (IL) | 2015-08-27 | — | — | US | disclosed |
| WO-2014041565-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2014-03-20 | — | — | WO | disclosed |
| CN-101701006-B | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LTD | 2014-03-05 | — | — | CN | disclosed |
| CN-103288793-A | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-1585633-B | Phenylethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD | 2010-10-27 | — | — | CN | disclosed |
| CN-101701006-A | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LTD | 2010-05-05 | — | — | CN | disclosed |
| CN-1302007-C | 17 beta-thiocarboxylic ester derivatives of androstanes with a cyclic ester group in the 17 alpha position having anti-inflammatory properties | GLAXO GROUP LTD (GB) | 2007-02-28 | — | — | CN | disclosed |
| CN-1585633-A | Phenylethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2005-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | VAT1, VKORC1L1, VKORC1 | ADRB2 1369/4885CYP3A4 7/4885SERPINE1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.